ARCH Venture Partners

www.archventure.com/about

VCMatch tracks ARCH Venture Partners as an investor focused on Biotech, Pharma, and Medtech companies, Pre-Seed and Seed rounds, United States, China, and Europe markets, and $50k check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$50k

Stages

Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage

Focus Areas

Biotech, Pharma, Medtech

Geography

United States, China, and Europe

Investment Thesis

ARCH is a science-first, company-creation focused venture firm that takes a contrarian, long-term approach to building disruptive companies. They found and back companies around “revolutionary technologies” by following the underlying science rather than market fashions, and provide flexible capital and hands-on support from formation through growth.

They emphasize flexibility in investment sizing and a willingness to take imaginative risks, leveraging an extended network of partners and deep operating/industry expertise to help portfolio companies reach their full potential.

Is ARCH Venture Partners right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

ARCH Venture Partners is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Pharma, Medtech, and Digital Health, especially across United States, China, and Europe, with public check-size signals around $50k.

Focus statement

ARCH focuses on founding and funding disruptive science companies (primarily in life sciences and adjacent physical/deep technology areas), investing across stages with check sizes “as little as $50K to as much as hundreds of millions of dollars, per company,” and helping companies from formation through scale.

Value Add

Science-first company formation: emphasis on founding companies based on “revolutionary technologies” rather than following market trends.
Contrarian, risk-tolerant stance: explicitly frames itself as willing to take bold and imaginative risks.
Wide and flexible capital deployment: public statement of backing companies with “as little as $50K to as much as hundreds of millions of dollars, per company.”
Long-term, hands-on support: “We take a long-term view when building companies” and provide formation-stage support through growth.
Extensive network of partners and senior venture/industry leaders embedded as Venture Partners and advisors (numerous named partners and experienced executives).
Proven track record of company creation and exits across life and physical sciences (portfolio examples and co-founders listed).